SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
The field of Cellular Immunotherapy has rapidly evolved over the past decade. Since the first Food and Drug Administration (FDA) approval of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) in 2017, the list of approvals expanded to include brexucabtagene autoleucel (Tecartus) in 2020, lisocabtagene maraleucel (Breyanzi) in 2021, idacabtagene vicleucel (Abecma) in 2021, and ciltacabtagene autoleucel (Carvykti) in 2022.1-9 In addition, cellular therapies are being studied earlier in the treatment course for patients with relapsed lymphoma and multiple myeloma.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima Source Type: research
More News: Food and Drug Administration (FDA) | Hematology | Immunotherapy | Leukemia | Lymphoma | Myeloma